The stock price of NeuroPace Inc (NASDAQ: NPCE) has jumped by 5.80 compared to previous close of 13.45. Despite this, the company has seen a gain of 17.70% in its stock price over the last five trading days. globenewswire.com reported 2025-02-20 that MOUNTAIN VIEW, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) — NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it has completed the previously announced plan to repurchase 5,270,845 shares of the Company’s common stock from KCK Ltd. The repurchase of these shares allowed for the organized sale by KCK Ltd. of all remaining shares it held in the Company. NeuroPace funded the repurchase of these shares using a portion of the proceeds from its recent underwritten public offering. NeuroPace also strengthened its balance sheet following the closing of the public offering, which the Company now anticipates will be sufficient to support its planned operations until achieving cash flow breakeven. Additionally, the Company terminated its current at-the-market (ATM) offering program.
Is It Worth Investing in NeuroPace Inc (NASDAQ: NPCE) Right Now?
NPCE has 36-month beta value of 2.05. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NPCE is 15.59M, and currently, short sellers hold a 1.41% ratio of that float. The average trading volume of NPCE on February 21, 2025 was 152.86K shares.
NPCE’s Market Performance
NPCE’s stock has seen a 17.70% increase for the week, with a 8.96% rise in the past month and a 58.46% gain in the past quarter. The volatility ratio for the week is 12.64%, and the volatility levels for the past 30 days are at 8.61% for NeuroPace Inc The simple moving average for the past 20 days is 5.13% for NPCE’s stock, with a 61.82% simple moving average for the past 200 days.
Analysts’ Opinion of NPCE
Many brokerage firms have already submitted their reports for NPCE stocks, with UBS repeating the rating for NPCE by listing it as a “Buy.” The predicted price for NPCE in the upcoming period, according to UBS is $17 based on the research report published on January 21, 2025 of the current year 2025.
Wells Fargo, on the other hand, stated in their research note that they expect to see NPCE reach a price target of $20, previously predicting the price at $16. The rating they have provided for NPCE stocks is “Overweight” according to the report published on March 14th, 2024.
Leerink Partners gave a rating of “Outperform” to NPCE, setting the target price at $22 in the report published on January 30th of the previous year.
NPCE Trading at 14.98% from the 50-Day Moving Average
After a stumble in the market that brought NPCE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.60% of loss for the given period.
Volatility was left at 8.61%, however, over the last 30 days, the volatility rate increased by 12.64%, as shares surge +1.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.15% upper at present.
During the last 5 trading sessions, NPCE rose by +17.70%, which changed the moving average for the period of 200-days by +2.37% in comparison to the 20-day moving average, which settled at $13.54. In addition, NeuroPace Inc saw 27.17% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NPCE starting from KCK LTD., who sale 5,270,845 shares at the price of $9.40 back on Feb 20 ’25. After this action, KCK LTD. now owns 0 shares of NeuroPace Inc, valued at $49,545,943 using the latest closing price.
Morrell Martha, the CHIEF MEDICAL OFFICER of NeuroPace Inc, sale 200 shares at $15.00 during a trade that took place back on Jan 30 ’25, which means that Morrell Martha is holding 86,762 shares at $3,000 based on the most recent closing price.
Stock Fundamentals for NPCE
Current profitability levels for the company are sitting at:
- -0.3 for the present operating margin
- 0.74 for the gross margin
The net margin for NeuroPace Inc stands at -0.37. The total capital return value is set at -0.28. Equity return is now at value -214.55, with -28.72 for asset returns.
Based on NeuroPace Inc (NPCE), the company’s capital structure generated 0.88 points at debt to capital in total, while cash flow to debt ratio is standing at -0.22. The debt to equity ratio resting at 7.48. The interest coverage ratio of the stock is -2.61.
Currently, EBITDA for the company is -22.83 million with net debt to EBITDA at -3.31. When we switch over and look at the enterprise to sales, we see a ratio of 6.32. The receivables turnover for the company is 6.61for trailing twelve months and the total asset turnover is 0.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.59.
Conclusion
To put it simply, NeuroPace Inc (NPCE) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
